Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Kafrit Industries on acquisition of Addvanze
Mandate

Vinge advises Kafrit Industries on acquisition of Addvanze

May 11, 2021 Employment and Benefits Banking and Finance Intellectual Property IT, Telecommunications and Outsourcing M&A Real Estate and Construction Commercial Agreements

Vinge advises Kafrit Industries (1993) Ltd on acquisition of Addvanze AB.

Kafrit Industries (1993) Ltd is an innovative and world leading producer of customized Masterbatches and Compounds for the plastic industry. For over 40 years Kafrit and its subsidiaries have been selling unique products and giving added value to well known customers around the world. Addvanze AB is a leading producer of the masterbatch in Europe.

Vinge’s team consisted of, among others, partners Christina Kokko and Matthias Pannier and associates Isabelle Jengsell and Amanda Steen (M&A), Isabell Nielsen (Agreements), Ludvig Wettergren and Karl-Gustaw Tobola (Banking and finance), Sara Strandberg (Employment), Sofia Bergenstråhle (IPR), Karl-Hugo Engdahl (IT/GDPR), Lina Österberg (Real Estate and environment) and VDR assistant Nathalie Hughes.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025